NCT05906836View on ClinicalTrials.gov

A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

July 27, 2023

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions

Healthy

Interventions

DRUG

Rosuvastatin

Administered orally.

DRUG

Selpercatinib

Administered orally.

Trial Locations (1)

75247

Labcorp Clinical Research LP, Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY